Document is current
Any future updates will be listed below
-
Authors
,
Ruth, Katherine S
Day, Felix R http://orcid.org/0000-0003-3789-7651
Tyrrell, Jessica
Thompson, Deborah J
Wood, Andrew R
Mahajan, Anubha
Beaumont, Robin N
Wittemans, Laura
Martin, Susan http://orcid.org/0000-0001-8746-0947
Busch, Alexander S. http://orcid.org/0000-0003-4417-569X
Erzurumluoglu, A. Mesut http://orcid.org/0000-0003-1322-8138
Hollis, Benjamin
O’Mara, Tracy A. http://orcid.org/0000-0002-5436-3232
McCarthy, Mark I
Langenberg, Claudia http://orcid.org/0000-0002-5017-7344
Easton, Douglas F http://orcid.org/0000-0003-2444-3247
Wareham, Nicholas J
Burgess, Stephen http://orcid.org/0000-0001-5365-8760
Murray, Anna
Ong, Ken K
Frayling, Timothy M
Perry, John R. B.
- License Information
-
More Information
Article History
Received: 12 September 2019
Accepted: 3 January 2020
First Online: 10 February 2020
Competing interests
: The views expressed in this article are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. M.I.M. has served on advisory panels for Pfizer, NovoNordisk and Zoe Global, and has received honoraria from Merck, Pfizer, Novo Nordisk and Eli Lilly, and research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier and Takeda. As of June of 2019, M.I.M. is an employee of Genentech, and a holder of Roche stock. T.M.F. holds an MRC CASE studentship with GSK and has consulted for Sanofi, Servier and Boerhinger Ingelheim.
